Skip to main content
Equibles
INGN logo

INGN · Inogen Inc · Metrics

Track INGN — free

Use INGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.91 -0.86 (-12.70%) Play latest call Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$179.66M
Shares
26.54M
Volume · Nov 6 974.93K Avg daily vol (3M) 316.16K

INGN metrics

83 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$6.03
Market cap
$179.66M

Price action

23 metrics
Price change (1W)
-6.7%
Price change (30D)
+16.3%
Price change (3M)
+4.3%
Price change (6M)
-5.8%
Price change (YTD)
+0.7%
Price change (1Y)
-8.4%
Trailing year
Price change (5Y)
-81.7%
52-week high
$7.39
52-week low
$5.09
Change from 52-week high
-8.4%
Change from 52-week low
+33.0%
Annualized volatility
44.2%
Annualized volatility (3M)
45.7%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.7
RSI (14D)
54.8
Price vs SMA 50
+13.8%
Price vs SMA 200
+8.5%
Avg volume (3M)
305,516
Relative volume
1.0
Average dollar volume
$1.79M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
26.54M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.5×
reciprocal yield 197.2%
P / book
1.0
reciprocal yield 97.3%
FCF yield
-2.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-13.7%

Historical valuation

8 metrics
P / E historical average (3Y)
77.5×
reciprocal yield 1.3%
P / E historical average (5Y)
77.5×
reciprocal yield 1.3%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-05

Profitability

9 metrics
Gross margin
44.5%
Operating margin
-8.7%
Trailing 12 months
Net margin
-6.9%
Gross profit (TTM)
$157.69M
Operating profit (TTM)
−$30.85M
Net income (TTM)
−$24.59M
Trailing 12 months
Diluted EPS (TTM)
$-0.90
FCF margin
-1.4%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$13.05
Gross profit per diluted share (TTM)
$5.81
Operating profit per diluted share (TTM)
$-1.14
EBITDA per diluted share (TTM)
$-0.41
Net income per diluted share (TTM)
$-0.90
Operating cash flow per diluted share (TTM)
$-0.09
Free cash flow per diluted share (TTM)
$-0.18
Capital expenditures per diluted share (TTM)
$0.09
R&D per diluted share (TTM)
$0.78
Stock compensation per diluted share (TTM)
$0.27
Book value per share
$7.06

Growth

11 metrics
Revenue growth YoY
+3.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$354.30M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.3%
Year over year · more shares
Revenue CAGR (3Y)
-2.6%
Revenue CAGR (5Y)
+2.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-14.1%
Return on assets
-8.6%
Debt / equity
—
Current ratio
2.7
EBITDA (TTM)
−$11.04M
Free cash flow (TTM)
−$4.98M
Quick ratio
2.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$87.28M
Total assets
$285.57M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$2.52M
Capital expenditures (TTM)
$2.47M
R&D (TTM)
$21.12M
SG&A (TTM)
—
Stock compensation (TTM)
$7.29M
R&D / revenue
6.0%
Stock compensation / revenue
2.1%

Ownership (13F)

9 metrics
13F filers
129
13F filer change QoQ
+2
Institutional ownership
72.5%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
28.5%
Private-fund adviser ownership
26.9%
Active holders' share change QoQ
+2.3%
Holder tenure
14.6
Price vs estimated holder cost
-25.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
11.4%

Short interest

3 metrics
Short interest
5.8%
Latest settlement · 4.1 days to cover
Days to cover
4.1d
Short-squeeze score
76 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1294133 CUSIP 45780L104 13F (30d) 49 filings 37 filers Visit website Investor relations